We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1326
Option Care Health
OPCH
$3.58B
| $518K | ﹤0.01% |
15,942
-1,089
| -6% | -$35.2K |
|
1327
Genworth Financial
GNW
$3.77B
| $515K | ﹤0.01% |
66,225
+195
| +0.3% | +$1.36K |
|
1328
Public Service Enterprise Group
PEG
$36.3B
| $512K | ﹤0.01% |
6,081
-325
| -5% | -$26.2K |
|
1329
The GEO Group
GEO
$4.31B
| $511K | ﹤0.01% |
21,349
-799
| -4% | -$21.8K |
|
1330
Vontier
VNT
$4.46B
| $509K | ﹤0.01% |
13,807
-346,096
| -96% | -$11.8M |
|
1331
Crown Castle
CCI
$32.2B
| $509K | ﹤0.01% |
4,955
+261
| +6% | +$26.4K |
|
|
HOLX
1332
DELISTED
Hologic
HOLX
| $504K | ﹤0.01% |
7,730
-418
| -5% | -$25.1K |
|
1333
Beam Therapeutics
BEAM
$3.02B
| $496K | ﹤0.01% |
29,165
-964
| -3% | -$16.8K |
|
1334
Conagra Brands
CAG
$7.67B
| $495K | ﹤0.01% |
24,206
+2,798
| +13% | +$65.6K |
|
1335
Envista
NVST
$4.35B
| $495K | ﹤0.01% |
25,350
-1,150
| -4% | -$20K |
|
1336
Home BancShares
HOMB
$5.94B
| $488K | ﹤0.01% |
17,143
-364
| -2% | -$10.1K |
|
1337
FirstCash
FCFS
$9.55B
| $487K | ﹤0.01% |
3,603
-84
| -2% | -$10.7K |
|
1338
HF Sinclair
DINO
$17.6B
| $483K | ﹤0.01% |
11,762
-3,382
| -22% | -$116K |
|
1339
United Bankshares
UBSI
$6.47B
| $482K | ﹤0.01% |
13,230
-288
| -2% | -$10.1K |
|
1340
Shift4
FOUR
$3.49B
| $482K | ﹤0.01% |
4,859
-144
| -3% | -$12.6K |
|
1341
Corcept Therapeutics
CORT
$12.3B
| $480K | ﹤0.01% |
6,537
-6,335
| -49% | -$459K |
|
1342
Blackstone
BX
$107B
| $475K | ﹤0.01% |
3,175
-42
| -1% | -$5.77K |
|
1343
Alphatec Holdings
ATEC
$1.46B
| $474K | ﹤0.01% |
+42,723
| New | +$491K |
|
1344
VeriSign
VRSN
$26.5B
| $474K | ﹤0.01% |
1,642
+849
| +107% | +$230K |
|
1345
Gold Fields
GFI
$40.7B
| $474K | ﹤0.01% |
20,027
| – | – |
|
1346
Lumentum
LITE
$81.3B
| $474K | ﹤0.01% |
4,985
+338
| +7% | +$24K |
|
1347
Gentex
GNTX
$4.82B
| $471K | ﹤0.01% |
21,414
-1,598
| -7% | -$34.9K |
|
1348
Boise Cascade
BCC
$2.73B
| $467K | ﹤0.01% |
5,384
+67
| +1% | +$6.07K |
|
1349
Bank OZK
OZK
$5.38B
| $464K | ﹤0.01% |
9,863
-127
| -1% | -$5.56K |
|
1350
AutoNation
AN
$6.67B
| $461K | ﹤0.01% |
2,323
-118
| -5% | -$21.3K |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.